Sat.Aug 31, 2024

article thumbnail

STAT+: A ‘tie-breaker’ study of Abbott’s heart clip brings more questions than answers

STAT

A study meant to serve as a tie-breaker between two major trials of a heart clip made by Abbott may end up stimulating more debate among cardiologists. Results of the RESHAPE-HF 2 trial, presented at the European Society of Cardiology meeting and published in the New England Journal of Medicine on Saturday, showed that the clip improved health status and lowered hospitalizations due to heart failure, but did not reduce the number of deaths.

Hospitals 250
article thumbnail

Weight-loss drugs ‘slow down the ageing process’, scientists suggest

The Guardian - Pharmaceutical Industry

Semaglutide – contained in Ozempic and Wegovy – has ‘far-reaching benefits’, with people dying at lower rate from all causes Weight-loss drugs are poised to revolutionise healthcare by slowing down the ageing process and by allowing people to live for longer and in better health. That is the dramatic message from leading scientists after studies were presented last week at the European Society of Cardiology Conference in London.

111
111
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Diabetes duration has minimal impact on SGLT2 inhibitor efficacy, as per new analysis

Pharmaceutical Technology

A meta-analysis has demonstrated consistent efficacy in heart failure outcomes with SGLT2 inhibitors regardless of disease duration.

article thumbnail

Drug Patent Expirations for the Week of September 1, 2024

Drug Patent Watch

EPIDUO (adapalene; benzoyl peroxide) Galderma labs lp Patent: 7,964,202 Expiration: Sep 1, 2024 See More … Source

52
article thumbnail

Navigating Payroll Compliance: Future-Proofing Payroll in an Evolving Regulatory Landscape

Speaker: Jennifer Hill

Payroll compliance is a cornerstone of business success, yet for small and midsize businesses, it’s becoming increasingly challenging to navigate the ever-evolving landscape of federal, state, and local regulations. Mistakes can lead to costly penalties and operational disruptions, making it essential to adopt advanced solutions that ensure accuracy and efficiency.

article thumbnail

ESC 2024: Study highlights potential for Novartis to differentiate in HF space

Pharmaceutical Technology

There is a strong opportunity in the heart failure (HF) space for new agents that could reduce HF-associated hospitalisations and mortality.

59